Literature DB >> 7617810

Myo-inositol attenuates the enhancement of the serotonin syndrome by lithium.

O Kofman1, U Levin.   

Abstract

Lithium elicits opposite effects on two behavioural syndromes in rats: enhancement of the 5-HT1A-linked serotonin syndrome and attenuation of the 5-HT2-linked wet dog shakes. The ability of intracerebroventricular (ICV) myo-inositol or forskolin to reverse the enhancement of the serotonin syndrome by lithium was tested in rats that were fed chronic dietary lithium or control diet and injected with the serotonin agonist 5-MeODMT (5-methoxy-N, N-dimethyltryptamine). Lithium enhanced the total serotonin syndrome score and particularly flat posture and tremor. Inositol, but not forskolin, mitigated the effects of lithium. Inositol was also injected in the lateral ventricle of rats pretreated with chronic dietary lithium or regular rat chow for 3 weeks and injected with carbidopa and L-5-hydroxytryptophan (5-HTP). Lithium attenuated wet dog shakes, but inositol had no significant effect on lithium-treated or control rats. These findings suggest that the enhancement of the serotonin syndrome by lithium may be related to lithium-induced inositol depletion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617810     DOI: 10.1007/BF02245842

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects.

Authors:  H K Manji; J K Hsiao; E D Risby; J Oliver; M V Rudorfer; W Z Potter
Journal:  Arch Gen Psychiatry       Date:  1991-06

2.  "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity.

Authors:  P Bedard; C J Pycock
Journal:  Neuropharmacology       Date:  1977-10       Impact factor: 5.250

3.  Serotonin receptor sensitivity after acute and chronic treatment with mianserin.

Authors:  M A Blackshear; E Sanders-Bush
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

4.  Effects of lithium chloride on parameters biosynthetic capacity for 5-hydroxytryptamin in rat brain.

Authors:  S Knapp; A J Mandell
Journal:  J Pharmacol Exp Ther       Date:  1975-06       Impact factor: 4.030

5.  Single and combined effects of desimipramine and lithium on serotonergic receptor number and second messenger function in rat brain.

Authors:  M E Newman; D Drummer; B Lerer
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

6.  Desensitization of muscarinic stimulated hippocampal cell firing is related to phosphoinositide hydrolysis and inhibited by lithium.

Authors:  N J Pontzer; F T Crews
Journal:  J Pharmacol Exp Ther       Date:  1990-06       Impact factor: 4.030

7.  Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizures.

Authors:  O Kofman; W R Sherman; V Katz; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Chloroamphetamine did not prevent the effects of chronic antidepressants on 5-hydroxytryptamine inhibition of forskolin-stimulated adenylate cyclase in rat hippocampus.

Authors:  M E Newman; A Ben-Zeev; B Lerer
Journal:  Eur J Pharmacol       Date:  1991-07-12       Impact factor: 4.432

9.  Effect of lithium on the prolactin response to D-fenfluramine in healthy subjects.

Authors:  A C Power; C E Dorkins; P J Cowen
Journal:  Biol Psychiatry       Date:  1993 Jun 1-15       Impact factor: 13.382

10.  The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.

Authors:  J F Deakin; A R Green
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

View more
  1 in total

Review 1.  A narrative synthesis of research with 5-MeO-DMT.

Authors:  Anna O Ermakova; Fiona Dunbar; James Rucker; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2021-10-19       Impact factor: 4.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.